ABB and Aventis sign Global Partnership Agreement

Harmonization with ABB’s IndustrialIT reduces costs

June 10, 2002. Recently representatives of Aventis Pharma and ABB met to sign a Partnership Agreement that will provide a broader, new, global basis for long-standing collaboration between the two companies in the field of process automation. The signing of this Agreement comes from years of cooperation and good relationships between Aventis and ABB.

“What really matters to us is the establishment and exchange of automation and product know-how,” says Dr. Hanns-Eberhard Erle, Head of the API Operations Business Unit at Aventis Pharmaceuticals. Erle sees the development of engineering standards as an important starting point for fruitful collaboration. Furthermore, Aventis attaches importance to a clear cost structure for later migrations to ABB’s IndustrialIT platform and to meeting FDA requirements relating to validation guideline 21 CFR Part 11.

“ABB is giving Aventis a long-term perspective not only with the technical development of our IndustrialIT systems, but also with cost reductions in hardware, software and life cycle support,” explains John Wilson, ABB’s Group Vice President of Chemicals/Pharmaceuticals Business Unit. The client’s software requirements are therefore included early on in product development at ABB.

An important part of the contract involves validation documentation – for pharmaceutical companies today an indispensable and cost-effective item in the production of medicinal substances. “Aventis and ABB have optimized the procedure of compiling such documents to mutual advantage,” comments Manfred Rothen, ABB’s Global Key Account Manager for Aventis. “Duplication or superfluous documentation can be avoided in this way – a significant cost factor,” continued Rothen.

But there is also potential for the mutual strengthening of business links in regular training to increase system know-how and in the periodic exchange of experience at management level. “This applies, for example, to the preparation of quotations– a service which will become significantly easier, faster and more cost-effective for both the supplier and client as a result of international harmonization and standardization,” Rothen says with conviction. All in all, Aventis has high hopes of a significant reduction in costs and as a result, a reduction in cost of ownership for its production plants with ABB automation. Besides the cost aspect, in particular the long-term nature and stability of the business relationship also plays an important role for ABB.

Aventis (NYSE: AVE) is dedicated to improving life through the discovery and development of innovative pharmaceutical products. In 2000, Aventis generated group sales of $ 22.3 billion and employed around 92,500 people in its Pharmaceutical and Agriculture businesses. Corporate headquarters are in Strasbourg, France. For more information, please visit: www.aventis.com

ABB (www.abb.com) is a global leader in power and automation technologies that enable utility and industry customers to improve performance while lowering environmental impacts. ABB has some 152,000 employees in more than 100 countries.

    •   Cancel
      • Twitter
      • Facebook
      • LinkedIn
      • Weibo
      • Print
      • Email
    •   Cancel

    Contact us

    Page information:
    • Chemical Info
      Marcia Zemanek
      Communications Manager
      Tel: 440-585-6830
    • ABB Process Industries GmbH
      Rainer Hofmann
      Tel : (+49) 6196 800 1427
      Fax : (+49) 6196 800 1423
    seitp222 c1256c290031524bc1256bd50027ab74